Provided by Tiger Trade Technology Pte. Ltd.

Oragenics

0.5250
-0.0150-2.78%
Post-market: 0.5191-0.0059-1.12%19:30 EDT
Volume:56.51K
Turnover:29.99K
Market Cap:2.37M
PE:-0.15
High:0.5449
Open:0.5312
Low:0.5200
Close:0.5400
52wk High:1.45
52wk Low:0.4801
Shares:4.51M
Float Shares:4.41M
Volume Ratio:1.04
T/O Rate:1.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5875
EPS(LYR):-4.5629
ROE:-1307.06%
ROA:-171.49%
PB:0.65
PE(LYR):-0.12

Loading ...

Company Profile

Company Name:
Oragenics
Exchange:
AMEX
Establishment Date:
1996
Employees:
3
Office Location:
9015 Town Center Parkway,Suite 143,Lakewood Ranch,Florida,United States
Zip Code:
34202
Fax:
- -
Introduction:
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics. It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

Directors

Name
Position
Charles L. Pope
Director and Executive Chairman
Alan W. Dunton
Independent Director
Frederick W. Telling
Independent Director
John P. Gandolfo
Independent Director
Natasha Giordano
Independent Director
Robert C. Koski
Independent Director

Shareholders

Name
Position
Janet Huffman
Chief Executive Officer and Chief Financial Officer
Charles L. Pope
Director and Executive Chairman